Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 5/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 3/20 | 0.47 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | STK16 | O75716 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL783483 | 0.89 | KCNJ1 (0.53) | CYP11B2KCNJ1GPR55MEN1KMT2A | |
| SCHEMBL10234020 | 0.88 | KCNJ1 (0.49) | CYP11B2KCNJ1GPR55MEN1KMT2A | |
| SCHEMBL805366 | 0.84 | CYP11B2 (0.49) | CYP11B2KCNJ1GPR55MEN1KMT2A | |
| SCHEMBL783194 | 0.78 | KCNJ1 (0.58) | CYP11B2KCNJ1GPR55MEN1KMT2A | |
| SCHEMBL783487 | 0.77 | KCNJ1 (0.51) | CYP11B2KCNJ1GPR55CYP11B1 | |
| SCHEMBL782500 | 0.75 | KCNJ1 (0.50) | CYP11B2KCNJ1GPR55 | |
| SCHEMBL782548 | 0.74 | CYP11B2 (0.48) | CYP11B2KCNJ1GPR55MEN1KMT2A | |
| SCHEMBL21535172 | 0.74 | CYP11B1 (0.55) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL31260061 | 0.74 | CYP11B1 (0.55) | CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL1607295 | 0.73 | CYP11B2 (0.55) | CYP11B2MEN1KMT2ACYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430018-B1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYMTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-8455522-B2 | Benzoxazolone derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-06-04 | — | — | US | disclosed |
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071514-A1 | BENZOXAZOLONE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B2, CYP11B1, CYP21A2 | CYP11B2 1/4885KCNJ1 630/4885GPR55 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.